Crinetics Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on November 18, 2008. The company is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of new drugs for the treatment of rare endocrine diseases and endocrine-related tumors. The function of the endocrine pathway is to maintain homeostasis, and peptide hormones acting through G protein-coupled receptors or GPCRs are commonly used to regulate many aspects of physiology, including growth, energy, metabolism, gastrointestinal function and stress response.
